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was signiﬁcantly higher: $8877 versus $7597; P = 0.001. In patients who had a VTE 
event, mean cost of care was almost 26% ($3906) and 17% ($1935) higher for stays 
in short—and long-term facilities, respectively; P = 0.001. On average, Medicare paid 
26% ($4057), 17% ($2102), and 17% ($1149) more due to VTE events for patients 
discharged to a short- or long-term facility or an SNF, respectively. CONCLUSIONS: 
Regardless of discharge status, VTE events during initial hospitalization for THR/TKR 
signiﬁcantly increase total costs of a 1-year stay.
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OBJECTIVES: To evaluate direct costs associated with the use of valsartan/amlodipine 
single pill combination (SPC) therapy versus angiotensin receptor blocker (ARB) plus 
calcium channel blocker (CCB) free combination (FC) therapy in hypertensive 
patients. METHODS: Administrative claims data from the HealthCore Integrated 
Research Database (HIRDTM) were used to identify patients with ≥1 hypertension 
claim (ICD-9 codes 401.xx-404.xx) and ≥1 ﬁll for valsartan/amlodipine SPC or ARB/
CCB FC during the intake period 7/1/2007—9/30/2008. Only patients with ≥6 months 
pre- and post-index health plan eligibility were selected. Total health care costs, 
medical costs and pharmacy costs were aggregated over the follow-up period and 
annualized. Generalized linear models were used to control for baseline differences 
between the SPC and FC therapy groups and to compare annualized total costs, 
medical costs and pharmacy costs between SPC and FC groups, respectively. 
RESULTS: A total of 1,226 patients were identiﬁed in the SPC group and 280 patients 
in the FC group. After controlling for baseline differences, the SPC cohort ($6,402) 
had signiﬁcantly lower total health care costs compared with patients in the FC cohort 
($7,758), p = 0.0096. Similarly, the SPC group had lower medical costs ($4,408 vs. 
$5,517, p = 0.0373) and lower annual pharmacy costs ($1,864 vs. $2,074, p = 0.0417) 
compared to FC patients. CONCLUSIONS: Annual total costs were $1,356 lower for 
patients taking valsartan/amlodipine single pill combination therapy as compared to 
patients taking ARB/CCB free combination therapy, suggesting that treatment of 
hypertensive patients with valsartan/amlodipine single pill combination therapy may 
result in cost savings compared to ARB/CCB free combination therapy.
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OBJECTIVES: To compare compliance/persistence, health care utilization, and costs 
associated with select antihypertensive single-pill combination (SPC) vs. free combina-
tion (FC) therapies among adult hypertension patients at both the national and state 
level. METHODS: Adult hypertension patients initiated on SPC or FC with angioten-
sin receptor blocker (ARB) + calcium channel blocker, ARB + hydrochlorothiazide, 
or angiotensin-converting enzyme inhibitors + hydrochlorothiazide were identiﬁed in 
the MarketScan Database (2006–2008). Study outcomes during the 6-month study 
period included medication possession ratio (MPR), treatment discontinuation rates, 
inpatient and emergency room (ER) visits, and changes in health care costs (study 
period minus baseline). Multivariate regression models examined the effect of SPC (vs. 
FC) use and its regional variation on outcomes, controlling for demographics, comor-
bidities, prescription use, and health care utilization during the baseline period (6 
months pre-therapy initiation). Regression-adjusted differences in outcomes between 
SPC vs. FC patients and associated 95% conﬁdence intervals (CIs) were estimated for 
the average patient in the U.S. and within each state. RESULTS: Adjusting for baseline, 
SPC patients (N = 382,476) demonstrated signiﬁcantly higher MPR (difference = 9.4% 
[95% CI: 9.2%, 9.5%]) and were less likely to discontinue treatment (odds ratio = 
0.535 [95% CI: 0.528, 0.542]) than FC patients (N = 197,375) nationwide. SPC 
patients had signiﬁcantly less hospitalizations and ER visits than FC patients, including 
29% fewer cardiovascular-related hospitalizations (adjusted incidence rate ratio = 0.71 
[95% CI: 0.69, 0.72]). Compared to FC, SPC patients showed signiﬁcantly greater 
reductions post-therapy initiation in all-cause medical costs by −$208 (95% CI: −$302, 
−$114), but larger increases in hypertension-related prescription costs by $53 (95% 
CI: $51, $55). State-level results were generally consistent in magnitude and trend for 
compliance and utilization outcomes, with greater regional variation in costs. CON-
CLUSIONS: SPC was associated with signiﬁcantly better compliance/persistence and 
lower frequencies of hospitalizations and ER visits compared to FC in hypertension 
patients. Larger reductions in medical costs with SPC offset small increases in drug 
costs.
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OBJECTIVES: To compare compliance/persistence, health care utilization, and costs 
associated with aliskiren + ARB vs. ARB + ACEI combination therapies among adult 
patients with hypertension. METHODS: Patients with hypertension (age≥18) initiated 
on combination therapy (≥15 days of overlap) with aliskiren + ARB or ARB + ACEI 
during July 2007-June 2008 were identiﬁed in the MarketScan Database. Study out-
comes were measured during the 6-month study period, including medication posses-
sion ratio (MPR), treatment discontinuation rates, resource utilization, and changes 
in health care costs (from 6-month baseline to study period). Risk-adjusted differences 
in outcomes between aliskiren + ARB vs. ARB + ACEI patients and their 95% conﬁ-
dence intervals (CIs) were estimated using multivariate regression models, controlling 
for demographics, comorbidities, prescription drug use, and health care resource 
utilization during the baseline period. RESULTS: Comorbidity proﬁles were similar 
between patients on aliskiren + ARB (N = 1,395) vs. ARB + ACEI (N = 16,507), 
though baseline resource utilization and costs were different between the cohorts. 
Adjusting for baseline characteristics, aliskiren + ARB patients demonstrated signiﬁ-
cantly higher MPR (difference = 15.2% [95% CI: 13.0%, 17.4%]) and lower discon-
tinuation rate (odds ratio = 0.43 [95% CI: 0.37, 0.51]) than ARB + ACEI patients. 
Aliskiren + ARB patients had fewer all-cause hospitalizations (adjusted incidence rate 
ratio [IRR] = 0.73 [95% CI: 0.61, 0.86]) and fewer all-cause emergency room (ER) 
visits (adjusted IRR = 0.72 [95% CI: 0.61, 0.85]) than ARB + ACEI patients; results 
for cardiovascular-related hospitalizations and ER visits were similar. Compared to 
ARB + ACEI patients, aliskiren + ARB patients had larger increases in prescription 
costs by $264 during the 6 months following therapy initiation (95% CI: $153, $375), 
but showed a trend in reducing total health care costs by −$583 (95% CI: −$2,409, 
$1,242) during the same 6-month period. CONCLUSIONS: Patients with hyperten-
sion initiated on aliskiren + ARB had signiﬁcantly better compliance/persistence and 
lower frequencies of hospitalizations and ER visits than those initiated on ARB + 
ACEI. Trends indicated greater reductions in total health care costs with aliskiren + 
ARB, despite increased prescription costs.
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OBJECTIVES: The incidence and incremental additional cost of surgical site infections 
(SSIs) for common cardiothoracic surgical procedures are not well characterized. Our 
study was designed to estimate the cost of several higher volume inpatient cardiotho-
racic surgical procedures to better characterize the burden of SSIs to hospitals and the 
health care system. METHODS: The Premier Perspective™ Database (PPD) was used 
to estimate the incidence and costs for SSIs in several common cardiothoracic surgical 
procedures using ICD-9 codes discharged between Q2 2006 and Q1 2009 from the 
over 600 US hospitals included in the PPD. PPD is the largest hospital-based, service-
level comparative database in the USA providing detailed resource utilization and cost 
data categorized under a patients’ principal and secondary diagnosis procedure codes. 
Our study focused on high volume cardiothoracic surgical procedures including 
sternum closure (3 codes), CABG (3 codes), and valve replacement (4 codes) to better 
estimate the incidence and costs of SSIs and the added costs to the health care system. 
RESULTS: The incidence of coded SSIs ranged between 1.9% to 6.3%, while the 
incremental additional costs for each SSI ranged between $30,395 and $67,722. The 
magnitude, therefore, of increased costs for each SSI was 2- to 6-fold higher compared 
with not having an SSI, depending on the cardiothoracic surgical procedure. 
CONCLUSIONS: The incidence of SSIs in several common cardiothoracic surgical 
procedures were relatively small (1.9%-6.3%), however, the increased costs ranged 
from 2- to 6-fold higher per SSI representing a substantial economic burden to hos-
pitals in the US health care system. New health care interventions targeted towards 
reducing the incidence of SSIs for common cardiothoracic procedures along the 
patient-care continuum are likely to reduce costs in both the short and long-term for 
hospitals in the US health care system.
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OBJECTIVES: Real world outcomes differences between valvular and non-valvular 
atrial ﬁbrillation is unknown. We identiﬁed these patients from U.S. claims data and 
compared the main outcomes differences to determine the economic and clinical 
burden of the disease. METHODS: We used U.S. medical and pharmacy claims data 
from 2005–2007 for the analysis. Patients aged 65 years and older who have had 2 
or more primary diagnoses for atrial ﬁbrillation occurring within 30 days of one 
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another were selected. Valvular and non-valvular patients were identiﬁed using appro-
priate ICD-9 codes. A bivariate comparison of baseline characteristics and outcomes 
measures was provided. T-test, Mann Whitney U-test, and chi square test were used 
based on the distribution and standardized differences were calculated. Risk adjust-
ment was done by using the propensity score method with the ProbChoice ™ algo-
rithm. RESULTS: Out of 19,268 identiﬁed patients, 392 were diagnosed with valvular 
atrial ﬁbrillation, and 18, 575 with non-valvular atrial ﬁbrillation. Patients were 
similar in terms of age and gender, but signiﬁcantly different in terms of comorbid 
conditions and baseline CHADS score. Patients with valvular atrial ﬁbrillation were 
more likely to have a Charlson comorbidity score, congestive heart failure, peripheral 
arterial disease, acute coronary syndrome, obesity, etc. Risk-adjusted outpatient visits 
(97% vs. 95%), transient ischemic attack (3.57 vs. 1.76), major bleeding (5.61 vs. 
2.86), and gastrointestinal bleeding (4.59 vs. 1.56) were all higher for patients with 
valvular atrial ﬁbrillation. However, risk-adjusted inpatient hospitalization (39.8% vs. 
44.77%) and osteoporotic fracture (0% vs. 1.66%) were lower. Overall risk-adjusted 
costs did not differ ($15, 426 vs. $16,059). CONCLUSIONS: Most of the adverse 
events analyzed were higher for valvular atrial ﬁbrillation patients relative to non-
valvular atrial ﬁbrillation patients. However, the economic burden of both groups of 
patients on the health care system was similar.
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OBJECTIVES: Patients with atrial ﬁbrillation (AF) are often chronically treated with 
anticoagulant or antiplatelet drugs for stroke prevention and are especially vulnerable 
to bleeding. The objective of this retrospective database analysis was to use administra-
tive claims data from a large, national US health care organization to examine the 
incremental costs of bleeding events in patients with AF. METHODS: Administrative 
claims data were used to identify patients with AF and bleeding events from January 
1, 2002—December 31, 2005 with continuous enrollment for 1 year prior to AF 
diagnosis. Patients were stratiﬁed into 3 sub-cohorts: intracranial hemorrhaging 
(ICH), major bleeds and minor bleeds. To assess incremental costs, patients with 
bleeding were matched on age, gender, region, and month of identiﬁcation to a cohort 
of patients with AF and no evidence of bleeding. Multivariate analyses were used to 
estimate the independent incremental cost attributed to bleeding. RESULTS: A total 
of 127,135 subjects were identiﬁed with AF, 39.1% of whom had bleeding events. 
After applying criteria for continuous enrollment and age (≥18 years), a total of 11,266 
patients that had evidence of bleeding were identiﬁed (1.8% ICH, 10.8% major bleeds 
and 87.4% minor bleeds). Compared to matched controls, patients with ICH or major 
bleed incurred signiﬁcantly more costs over the 1-year follow up period. Mean 
adjusted incremental total costs over the 1-year follow-up period were $258,968 in 
subjects with ICH and $88,775 in subjects with major bleeds. Patients with minor 
bleeds did not incur additional costs compared to controls. CONCLUSIONS: Major 
bleeding associated with AF is associated with signiﬁcant costs over and above that 
of AF alone. New strategies that further reduce the risk of bleeding among patients 
with AF could reduce the cost of their care.
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OBJECTIVES: This study sought to examine the direct medical costs of stroke based 
on the actual hospital charge data in the incidence based cohort. METHODS: We 
obtained the cost data for 884 stroke patients in 8 university hospitals. The cost 
data targeted for all adult patients (≥19 years) admitted for stroke during 2 month 
(between November 1 and December 31, 2006) and were assessed for 2 years. The 
target patients were primarily diagnosed as ‘Subarachnoid hemorrhage (I60)’, ‘Intra-
cerebral hemorrhage (I61)’, ‘Other nontraumatic intracranial hemorrhage (I62)’, 
‘Cerebral infarction (I63)’, and also categorized by history of stroke; ‘primary stroke 
(1st onset)’, ‘recurrent stroke’. RESULTS: According to diagnosis distribution, I60 
was diagnosed in 125 patients (14%), I61 in 158 patients (18%), I62 in 25 patients 
(3%) and I63 in 576 patients (65%). During study period, 85 patients (10%) were 
died and 471 patients (53%) were assessed for more than 1 year. The annual average 
direct medical costs for stroke (I60∼I63) were KRW 8,530,941 for the 1st year of 
onset, KRW 1,098,316 for the 2nd year of onset. This result indicated that the 1st 
year accounted for 89% of 2-year direct medical costs. Analysis by the diagnosis 
class also revealed that the 1st year direct medical costs for hemorrhagic stroke 
(I60∼I62) were KRW 13,518,895, which were more than double of costs for cerebral 
infarction (I63), KRW 5,863,771. The 2nd year costs were similar; KRW 1,055,934 
for hemorrhagic stroke and KRW 1,115,700 for cerebral infarction. When catego-
rized by history of stroke, the 1st year costs for primary stroke (KRW 8,837,111) 
were higher than those for recurrent stroke (KRW 5,988,121). CONCLUSIONS: 
This study is signiﬁcant in that it examined stroke costs including non-reimbursed 
costs based on the actual hospital charge data while previous studies depended on 
the insurance claim data in Korea.
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OBJECTIVES: There is very limited nationally representative data on the economic 
burden of venous thromboembolism (VTE), which manifests as deep vein thrombosis 
(DVT) or pulmonary embolism (PE). The objectives of this study were to assess 
charges and inpatient length of stay associated with DVT and PE among US hospital 
discharges. METHODS: Data were analyzed from the 2007 Nationwide Inpatient 
Sample (NIS), which is the largest all-payer inpatient care database in the U.S. contain-
ing all discharge data from 1044 hospitals in 40 US states, approximating a 20% 
stratiﬁed sample of US community hospitals. Using a combination of several ICD-
9-CM codes, hospital discharges were classiﬁed as those with a primary diagnosis of 
DVT, primary diagnosis of PE, secondary diagnosis of DVT, secondary diagnosis of 
PE and secondary diagnosis of DVT and PE. Hospital charges and length of stay were 
estimated for each of these VTE hospitalizations. RESULTS: Among all the 39,541,948 
hospital discharges in the US in 2007, 172,731 (0.44%) were primary DVT, 155,281 
(0.39%) were primary PE, 402,449 (1.02%) were secondary DVT, 118,557 (0.30%) 
were secondary PE and 30,473 (0.08%) were secondary DVT and PE. The mean 
length of stay for discharges with secondary DVT (11.3 days), secondary PE (12.0 
days), secondary DVT and PE (14.5 days) was substantially more than for discharges 
with primary DVT (4.9 days) and primary PE (5.8 days). Similarly, the mean (95% 
CI) total hospital charges for stays with secondary DVT ($73,152; $68,368–$77,935), 
secondary PE ($80,341; $74,782–$85,900), secondary DVT and PE ($98,205; 
$89,906–$106,503) was substantially more than for stays with primary DVT 
($23,771; $22,572–$24,970) and primary PE ($30,478; $28,912–$32,044). CON-
CLUSIONS: In 2007, the economic burden of VTE in US hospitals was estimated in 
aggregate at $4.07 billion for primary DVT and $4.65 billion for primary PE hospi-
talizations. Compared to primary VTE, the inpatient costs were substantially larger 
for secondary VTE.
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OBJECTIVES: To describe the relationship between the cost-sharing and antihyper-
tensive medication therapy of ﬁxed-dose combination (FDC) versus mono therapy. 
METHODS: Cross-sectional study of all individuals surveyed in the U.S. Medical 
Expenditure Panel Survey 2006 with at least one hypertension diagnosis, only 30 pills 
antihypertensive drugs per prescription, and either FDC or mono therapy were 
included. Bivariate and multivariate generalized linear regression models that con-
trolled for demographic, socioeconomic and drug characteristics assessed the associa-
tion between the costs and therapy type. Crude and adjusted mean out-of-pocket cost 
and total payers paid amount were also computed and compared. The 2006 full-year 
person level sample weight was applied in the statistical analysis. RESULTS: The 
cohort consist of 2,190 hypertension patients with a mean age of 60.3 years, 55.9% 
female, with average Charlson index of 0.36(rang 0–8) and 35% population were on 
FDC therapy. The multivariate model that adjusted for demographic, socioeconomic 
and drug factors, showed FDC therapy had no signiﬁcant association with out-of-
pocket cost with coefﬁcient(95% conﬁdential interval) of 1.0742(−0.9577 to 3.1061), 
but was negatively associated with the total cost with coefﬁcient of −6.6614(−10.1180 
to −3.2048). The crude average increase in out-of-pocket and total payer costs per 
patient with 30 pills per prescription between FDC versus mono therapy were 
$6.22(95% conﬁdence interval, $4.42 to 8.02) and $5.67($2.66 to 8.67), respectively, 
while the adjusted average increase in costs were $1.47($−0.29 to 3.23) and $2.00($−
1.02 to 5.01), respectively. CONCLUSIONS: The association results suggested that 
FDC antihypertensive therapy does not affect patient out-of-pocket cost, but FDC 
therapy reduces payer cost. Considering the number of agents in one pill of the 
therapy, FDC therapy does not cost signiﬁcantly more to patient and payer than mono 
therapy. Our results also provide economic evidence for clinicians to help ease the 
ﬁnancial burden from out-of-pocket cost in patients who need two antihypertensive 
agents therapy.
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OBJECTIVES: To summarize economic burden associated with treatment of venous 
thromboembolism (VTE) from payor, patient, and caregiver perspectives by assessing 
characteristics, outcomes, costs, and cost drivers of treatment. METHODS: We con-
ducted a systematic search of MEDLINE and EMBASE databases for US economic 
studies of VTE published between January 1, 1999 and May 22, 2009. We also 
reviewed bibliographies of included studies. Studies were critically appraised using the 
